Kamradt J M, Pienta K J
University of Michigan, Comprehensive Cancer Center and Division of Hematology/Oncology, Department of Internal Medicine, Ann Arbor, MI 48109, USA.
Oncol Rep. 1998 Jul-Aug;5(4):919-21. doi: 10.3892/or.5.4.919.
Prostate cancer remains the most commonly diagnosed cancer in American males and is the second leading cause of cancer death in this group. Hydrazine sulfate, an inhibitor of gluconeogenesis, has been proposed as a means to improve nutritional status and improve survival in patients with solid tumors. We investigated the effects of hydrazine sulfate on both in vitro and in vivo models of prostate cancer. We examined the cytotoxicity of hydrazine sulfate in both human (LNCaP and PC-3) and animal (MAT-LyLu) prostate cancer cell lines. No growth inhibition was observed. In vivo, hydrazine sulfate did not suppress the growth of implanted Dunning rat prostate MAT-LyLu cells. Hydrazine sulfate does not have activity in these models of prostate cancer and may not be an appropriate therapy for patients with prostate cancer.
前列腺癌仍然是美国男性中最常被诊断出的癌症，并且是该群体中癌症死亡的第二大主要原因。硫酸肼，一种糖异生抑制剂，已被提议作为改善实体瘤患者营养状况和提高生存率的一种手段。我们研究了硫酸肼对前列腺癌体外和体内模型的影响。我们检测了硫酸肼在人前列腺癌细胞系（LNCaP和PC-3）和动物前列腺癌细胞系（MAT-LyLu）中的细胞毒性。未观察到生长抑制。在体内，硫酸肼并未抑制植入的邓宁大鼠前列腺MAT-LyLu细胞的生长。硫酸肼在这些前列腺癌模型中没有活性，可能不是前列腺癌患者的合适治疗方法。
